THE WELCH COMPANY
440 Davis Court #1602
San Francisco, CA 94111-2496
415 781 5700
rodwelch@pacbell.net


S U M M A R Y


DIARY: January 8, 2009 08:00 AM Thursday; Rod Welch

Millie blood draw 3rd cycle sunitinib treatment at UCSF.

1...Summary/Objective
2...Schedule Blood Draws to Perform Laboratory Tests Sunitinib Treatment
....Date Time Staff Sta Type Dept Loc Dur Number Cycl
3...Labs Blood Test
4...NEUTS 0.87 Decrease Significant from Cheotherapy Sunitinib 2 Weeks
5...Blood Counts NEUTS 0.87 Fall With Cyclophosphamide Sunitinib 2 Weeks Weeks
6...Side Effects Neupogen Treatments Continue Mild Tolerance Acceptable
7...Coagulation Control INR 3.1 Above Range Treating Pulmonary Embolism


..............
Click here to comment!

CONTACTS 

SUBJECTS
Cetuximab Carboplatin Clinical Study 2nd Arm 7th Cycle 1st Treatment

1003 -
1003 -    ..
1004 - Summary/Objective
1005 -
100501 - Follow up ref SDS M4 0000. ref SDS L5 0000.
100502 -
100503 -
100504 -
100505 -
100507 -  ..
1006 -
1007 -
1008 - Progress
1009 -
100901 - Background on Millie's treatment in the clinical study is reported on
100902 - 080508. ref SDS A1 TZ8I
100904 -  ..
100905 - Treatment on the cetuximab Carboplatin clinical study was stopped by
100906 - Doctor Rugo on 081023, ref SDS K0 D65G, after 90 treatments with
100907 - cetuximab, and 21 treatments with Carboplatin on the 2nd arm of the
100908 - study. ref SDS J8 V94O
100910 -  ..
100911 - On 081016 Doctor Rugo proposed treating Millie with a clinical study
100912 - for sunitinib metronomic (low dose) protocol, that includes
100913 - cyclophosmphamide and Methotrexate. ref SDS J0 J38U  At that time, a
100914 - work plan was developed on 081016. ref SDS J0 J36R
100916 -  ..
100917 - Work plan was updated on 081029. ref SDS K6 LH4O
100919 -  ..
100920 - The sunitinib protocol requires daily oral treatment, and began on
100921 - 081114. ref SDS L2 505G  Millie takes these drugs in the mornings at
100922 - 0700, reported in another record today. ref SDS L4 505G
100924 -  ..
100925 - Background on transitioning to sunitinib is reported on 081107.
100926 - ref SDS K9 4F6G
100928 -  ..
100929 - On 081113 Millie had a blood draw for study tubes only to start the
100930 - new treatment with sunitinib; no lab reports were done, she was
100931 - welcomed back to the Infusion Clinic by the regular Thursday staff.
100932 - ref SDS L1 WV62
100934 -  ..
100935 - Sunitinib treatment started on 081114 for 2 weeks to evaluate
100936 - effectiveness, and tolerance of side effects. ref SDS L2 505G
100938 -  ..
100939 - The full sunitinib treatment protocol was begun 2 weeks later on
100940 - 081128. ref SDS L8 505G
100941 -
100942 -
100943 -
100944 -
100945 -
100946 -
1010 -

SUBJECTS
Default Null Subject Account for Blank Record

1703 -
170401 -  ..
170402 - Schedule Blood Draws to Perform Laboratory Tests Sunitinib Treatment
170403 -
170404 - Follow up ref SDS M4 1K7H, ref SDS L5 1K7H.
170406 -  ..
170407 - Neupogen scheduled through 090131 is listed on 081220. ref SDS M7 HS5M
170409 -  ..
170410 - Sunitinib is a "targeted" cancer treatment that has less effect on
170411 - blood counts.  Cyclophosphamide and Methotrexate are chemotherapy
170412 - drugs that reduce blood counts.  These drugs created problems for
170413 - Millie to maintain drug counts, reviewed with the medical team at UCSF
170414 - on 081218, ref SDS M5 QW7H  As a result, Doctor Rugo approved Neupogen
170415 - treatments on 081219 and 081220, ref SDS M7 P73J, and further paused
170416 - Millie's treatments entirely for a week, and eliminated Methotrexate
170417 - from the treatment protocol. ref SDS M5 QW49
170419 -  ..
170420 - Blood test on 081226 after pausing cancer treatment for a week showed
170421 - significant increase. ref SDS M8 OT8J
170423 -  ..
170424 - As a result, Millie's treatment with sunitinib resumed on 081227 at
170425 - full strength, along with cyclophosphamide, reported to the medical
170426 - team on 081230. ref SDS M9 JV5M
170428 -  ..
170429 - Case study on blood tests and dilemma maintaining blood counts in
170430 - order to continue with cancer treatments is reported on 081230.
170431 - ref SDS M9 I87N
170433 -  ..
170434 - Three (3) week cycles sunitinib protocol requires blood draws and
170435 - meetings with the medical team as follows...
170437 -  ..
170438 - During the meeting with the medical team, Glenna confirmed times for
170439 - meetings through 090402...
170441 -  ..
170442 - We need Nola to confirm times for Millie's blood draws.  She was not
170443 - in the office during Millie's blood draw at 0800 this morning.
170444 -
170445 -        [On 090108 Glenna submitted schedule for meetings with the
170446 -        doctor. ref SDS N1 UY3Y
170447 -
170448 -        [On 090115 Millie submitted a letter to Catherine and Diane
170449 -        asking for assistance getting blood tests scheduled at UCSF.
170450 -        ref SDS N2 485J
170452 -         ..
170453 -        [On 090121 Nola advised that Millie has been scheduled for
170454 -        blood draws as shown in the record today on 090108. ref SDS N3
170455 -        N57I
170457 -     ..
170458 -    Date  Time   Staff         Sta  Type  Dept   Loc  Dur  Number  Cycl
170459 -
170460 -    Follow up ref SDS M4 PN6F, ref SDS L5 PN6F.
170461 -
170462 -    090129 0800  Catherine    PEN  AC1  CCINF  INF  20            04
170463 -    090129 0830  Rugo         PEN  CHF  BCC    Z4F  30            04
170464 -                 Tara
170465 -                 Glenna
170466 -    090219 0800  Catherine    PEN  AC1  CCINF  INF  20            05
170467 -    090219 0900  Rugo         PEN  CHF  BCC    Z4F  30            05
170468 -                 Tara
170469 -                 Glenna
170470 -    090312 0800  Catherine    PEN  AC1  CCINF  INF  20            06
170471 -    090312 0830  Rugo         PEN  CHF  BCC    Z4F  30            06
170472 -                 Tara
170473 -                 Glenna
170474 -    090402 0800  Catherine    PEN  AC1  CCINF  INF  20            07
170475 -    090402 0830  Rugo         PEN  CHF  BCC    Z4F  30            07
170476 -                 Tara
170477 -                 Glenna
170478 -    090423 0800  Catherine    PEN  AC1  CCINF  INF  20            08
170479 -    090423 0830  Rugo         PEN  CHF  BCC    Z4F  30            08
170480 -                 Tara
170481 -                 Glenna
170482 -    090514 0800  Catherine    PEN  AC1  CCINF  INF  20            09
170483 -    090514 0830  Rugo         PEN  CHF  BCC    Z4F  30            09
170484 -                 Tara
170485 -                 Glenna
170486 -    090604 0800  Catherine    PEN  AC1  CCINF  INF  20            10
170487 -    090604 0830  Rugo         PEN  CHF  BCC    Z4F  30            10
170488 -                 Tara
170489 -                 Glenna
170490 -
170491 -
170492 -
1705 -

SUBJECTS
Blood Tests Labs Infusion Clinic Evaluate Safe Chemotherapy 1st Trea

2503 -
2504 - 0750
250501 -  ..
250502 - Labs Blood Test
250503 -
250504 - Follow up ref SDS M4 FW5N, ref SDS L5 FW5N.
250505 -
250506 - The sunitinib clincial study requires blood draws every 3 weeks, shown
250507 - in the record on 081017. ref SDS J1 6R6G  This is a significant change
250508 - from getting weekly blood draws the past 2 years on the cetuximab
250509 - protocol.
250511 -  ..
250512 - On 081113 Millie had a blood draw for study tubes only to start the
250513 - new treatment with sunitinib; no lab reports were done. ref SDS L1
250514 - WV62  The prior labs for the sunitinib study were done on 081107.
250515 - ref SDS K9 LO4G
250517 -  ..
250518 - On 081126 Millie had a blood draw to start the first cycle of the
250519 - study.  On 081210 she had a blood draw to test NEUTS for getting
250520 - Neupogen. ref SDS M2 S65I  There was a follow up lab at Kaiser on
250521 - 081212. ref SDS M3 S65I
250523 -  ..
250524 - Millie's last blood draw was at Kaiser on 081226. ref SDS M8 S65I
250526 -  ..
250527 - Catherine was Millie's nurse today for the blood draw...
250528 -
250543 -     ..
250544 -    Log#:                   090108 08:20
250545 -    <----------------------- U C S F -----------------------> <-------------  Kaiser -------------->
250546 -    Type                 Results   Units        Normal        ACRO   Type            Units        Normal
250547 -     ..
250548 -    CBC with DIFF & PLT CT                                     CBCD
250549 -     ..
250550 -    WBC COUNT      l        2.5    x10E9/L     3.4  -   10     WBC   WBC x10-3        K/uL     3.4  -  10.0
250551 -    RBC COUNT      l        2.95   x10E12/L      4  -   5.2    RBC   RBC x10-6        M/uL    3.60  -  5.70
250552 -    HEMOGLOBIN     l       10.4    g/dL         12  -   15.5   HGB   Hemoglobin       g/dL    11.5  -  15.0
250553 -    HEMATOCRIT     l       29.3    PERCENT      36  -   46     HCT   Hematocrit       %       34.0  -  46.0
250554 -    MCV                    99      fL           80  -   100    MCV   MCV              fL      80.0  -  100.0
250555 -    MCH            h       35.3    pg           26  -   34     MCH
250556 -    MCHC                   35.5    g/dL         31  -   36     MCHC
250557 -     ..
250558 -    PLATELETS             175      x10E9/L     140  -  450     PLT   Plt x10-3        K/uL     140  -  400
250559 -    ..
250560 -       (posted 090113, Catherine...
250561 -    CA 15-3      H*        99      U/mL             <  33     CA153  CA 15-3                        <  39
250562 -
250563 -         Note new reference range [<33 changed from <31] and change in
250564 -         methodology effective March 1, 2008.  Performed using the
250565 -         Siemens Centaur Chemiluminesence method.  CA 15-3 result using
250566 -         the Roche Elecsys assay is 75 U/mL.  Ref range <31 U/mL.  This
250567 -         rebaseline value provided at no additional charge.
250569 -          ..
250570 -         This new note updates explanation of tests prior to 080301,
250571 -         e.g., on 080207. ref SDS 74 A16M
250572 -    ..
250573 -     (NEUTS x 1000 = ANC for Kaiser)
250574 -    NEUTS          L        0.87   x10E9/L     1.8  -  6.8     N-A   ANC                      1500
250575 -    Neutrophils    Not Reported                                      Neutrophils       %        50  -  70
250577 -     ..
250578 -    LYMPHS                  1.01   x10E9/L     0.9  -  2.9     L-A   Lymphocytes       %        20  -  50
250579 -    MONOS            l      0.12   x10E9/L     0.2  -  0.8     M-A   Monocyte          %         0  -  11
250580 -    EOS              h      0.42   x10E9/L     0.0  -  0.4     E-A   Esoinophils       %         1  -  5
250581 -    BASOS                   0.05   x10E9/L     0.0  -  0.1     B-A   Basophil          %         0  -  2
250582 -     ..
250583 -  * LUC/ATYP LYMPHS         0.08   x10E9/L     0.0  -  0.2     LALA
250585 -     ..
250586 -    <----------------------- U C S F -----------------------> <-------------  Kaiser -------------->
250587 -    Type                 Results   Units        Normal        ACRO   Type            Units        Normal
250588 -    PT              h      32.5    s          12.0  -  14.1    PT    PT, patient       sec     8.9  -  11.1
250589 -    INL NRM Ratio   h       3.1                0.9  -  1.1     INR   INR                       2.0  -  3.0
250590 -
250591 -        Performed at Mt Zion Clinic Lab, 1600 Divisadero, San
250592 -        Francisco, CA  94115
250594 -     ..
250595 -  * PARTIAL
250596 -    THROMBOPLASTIN  H [No report]  s          22.2  - 34.2     INR   PTT
250597 -
250598 -        Performed at Mt Zion Clinic Lab, 1600 Divisadero, San
250599 -        Francisco, CA  94115
250601 -     ..
250602 -  * FIBRINOGEN        [No report]  mg/dL       202  - 430      FIB
250603 -
250604 -        New test added today, 080818; Catherine says similar to INR.
250606 -     ..
250607 -    <----------------------- U C S F -----------------------> <-------------  Kaiser -------------->
250608 -    Type                 Results   Units        Normal        ACRO   Type            Units        Normal
250609 -    ELECTROLYTE PANEL                                          LYTE
250610 -    SODIUM                135      mmol/L      134  -  143     NA    Sodium            mEq/L   137  -  145
250611 -    POTASSIUM               4.5    mmol/L      3.4  -  4.9     K     Potassium         mEq/L   3.5  -  5.3
250612 -    CHLORIDE              100      mmol/L       98  -  107     CL
250613 -    CARBON DIOX TOTAL      25      mmol/L       23  -  32      CO2
250614 -    ANION GAP              10                    3  -  14      ANGA
250615 -     ..
250616 - *  UREA NITROGEN          14      mg/dL         8  -  23      BUN   BUN               mg/dL     7  -  17
250617 -    GLUCOSE       [No report]      mg/dL        70  -  199     GLU   Glucose           mg/dL     ?  -   ?
250618 -    AST            h       47      U/L          16  -  41      AST   AST (SGOT)        U/L      14  -  36
250619 -    ALT                    19      U/L          11  -  54      ALT   ALT (SGPT)        U/L      11  -  66
250620 -    BILIRUBIN, TOTAL        0.6    mg/dL       0.3  - 1.3      BILT  Bili Total        mg/dL   0.2  - 1.3
250621 -    ALKALINE PHOSPHATASE   53      U/L          29  - 111      ALKP  Alkaline Ph       U/L      38  - 126
250622 -     ..
250623 -    PROTEIN, TOTAL [No report]     g/dL        5.8  - 8.0      TP    Protine Total     g/dL    6.3  - 8.2
250624 -    ALBUMIN        [No report]     g/dL        3.4  - 4.7      ALB   Albumin           g/dL    3.4  - 4.8
250625 -    CALCIUM        [No report]     mg/dL       8.7  - 10.1     CA    Calcium           mg/dL   8.4  - 10.2
250626 -     ..
250627 -    MAGNESIUM               1.9    mg/dL       1.8  -  2.3     MG    Magnesium         mg/dL   1.6  -  2.3
250628 -    PHOSPHORUS     [No report]     mg/dL       2.4  -  4.6     PO4   Phosphorus
250630 -     ..
250631 -    CREAT with eGFR
250632 -    CREATININE              0.73   mg/dL      0.42  - 1.06     CR    Creatinine        mg/dL   0.6  -  1.2
250633 -
250634 -      Note: Creatinine assay changed to IDMS standardization on
250635 -      February 4, 2008 causing decrease in results of approximately
250636 -      0.09 mg/dL
250638 -     ..
250639 -    eGFR if Caucasian     >60      mL/min                      GFRC
250640 -    eGFR if African Amer  >60      mL/min                      GFRA
250641 -
250642 -      eGFR corrected for 1.73 sq meters of body surface area
250643 -      Note:  eGFR is only an estimation. Please see online Lab Manual
250644 -      for potential limitations.
250645 -      Performed at Mt Zion Clin Lab, 1600 Divisadero, San Francisco,
250646 -      CA  94115
250648 -     ..
250649 - *  Labs today 081023 included tests omitted on 081016 labs...
250650 -
250651 -            LUC/ATYP LYMPHS...................... ref SDS I9 Z47G
250653 -     ..
250654 -    Labs today 081023 omitted tests included on 081016 labs...
250655 -
250656 -            PARTIAL THROMBOPLASTIN............... ref SDS J8 GQ6F
250658 -     ..
250659 -    Labs included on 081016 tests omitted on 080918 labs...
250660 -
250661 -            LUC/ATYP LYMPHS...................... ref SDS I9 Z47G
250663 -     ..
250664 -    Labs omitted tests on 081016 included on 080918 labs...
250665 -
250666 -            PARTIAL THROMBOPLASTIN............... ref SDS H4 GQ6F
250667 -            FIBRINOGEN........................... ref SDS H4 VE6I
250669 -     ..
250670 -    Labs on 080821 omitted following tests...
250671 -
250672 -            GLUCOSE.............................. ref SDS F7 SE9J
250673 -            ALBUMIN.............................. ref SDS F7 GT9I
250674 -            PROTEIN, TOTAL
250676 -     ..
250677 -    Labs on 080726 omitted following tests...
250678 -
250679 -            GLUCOSE.............................. ref SDS D9 SE9J
250680 -            ALBUMIN.............................. ref SDS D9 GT9I
250682 -     ..
250683 -    Labs on 080626 omitted following tests...
250684 -
250685 -            GLUCOSE.............................. ref SDS B8 HS7I
250686 -            PROTEIN, TOTAL
250687 -            ALBUMIN
250688 -            CALCIUM
250690 -  ..
250691 - Case study on 080626 shows these four tests, which have been omitted
250692 - and included in various combinations the past 4 cycles, were
250693 - consistently included for the prevous 15 cycles. ref SDS B8 HS8F
250694 -
260420 -
260421 -
2605 -

SUBJECTS
Absolute Neutrophils Count ANC 6850 Above 1500 NEUTS 6.85 Above 1.5

3503 -
350401 -  ..
350402 - NEUTS 0.87 Decrease Significant from Cheotherapy Sunitinib 2 Weeks
350403 - Blood Counts NEUTS 0.87 Fall With Cyclophosphamide Sunitinib 2 Weeks   Weeks
350404 -
350405 - Follow up ref SDS M4 PU6K, ref SDS L5 PU6K.
350406 -
350407 - Blood counts decreased significantly shown by the Lab report today
350408 - with NEUTS 0.87, ref SDS 0 QY6H, compared with NEUTS 1.71 (ANC 1710) 2
350409 - weeks ago at Kaiser on 081226, ref SDS M8 B35J, This is below the UCSF
350410 - range of 1.00 for Millie to safely get chemotherapy treatment.
350412 -  ..
350413 - Blood counts decline from...
350414 -
350415 -                     1710 to 870    = 640 points
350416 -
350417 -                   081226 to 090108 = 12 days
350418 -
350419 -      Blood counts average decline  = 53 per day
350421 -  ..
350422 - Previously, on
350424 -  ..
350425 - Side effects of Neupogen are listed below. ref SDS I9 SB8I
350427 -  ..
350428 - The doctor prescribed Neupogen tomorrow and Saturday (090109 and
350429 - 090110) at Kaiser, and also paused treatment with cycolphosphamide
350430 - chemotherapy until NEUTS rise to 1.00.  This will be tested with
350431 - another blood draw at Kaiser on 090116.
350432 -
350433 -
350434 -
350435 -
3505 -

SUBJECTS
Default Null Subject Account for Blank Record

3603 -
360401 -  ..
360402 - Side Effects Neupogen Treatments Continue Mild Tolerance Acceptable
360403 -
360404 - Follow up ref SDS M4 SB8I, ref SDS L5 SB8I.
360405 -
360406 - Fitness from hiking is listed in case study on 081021. ref SDS J5 8G5M
360408 -  ..
360409 - Millie last reported side effects on 081011 experiencing bone pain,
360410 - headache, and fatigue associated with Neupogen and chemotherapy.
360411 - ref SDS I4 FL4H
360413 -  ..
360414 - Side effects of Neupogen may be lessening, reported on...
360415 -
360416 -               081011................, ref SDS I4 FL4H
360417 -               081010................, ref SDS I3 SB8I
360418 -               081006................, ref SDS I1 3E4K
360419 -               081004................, ref SDS I0 Y17L
360420 -               081002................, ref SDS H9 Y17L
360421 -               080930................, ref SDS H8 Y17L
360422 -               080923................, ref SDS H6 K16F
360423 -               080915................, ref SDS H1 9W9I
360424 -               080810................, ref SDS F3 9W9I
360425 -               080803................, ref SDS E4 9W9I
360426 -               080726................, ref SDS E1 9W9I
360427 -               080721................, ref SDS D6 9W9I
360428 -               080713................, ref SDS C9 RM94
360429 -               080629................, ref SDS C2 6Q5J
360430 -               080628................, ref SDS C0 6Q5J
360431 -
360432 -
360433 -
360434 -
360435 -
3605 -

SUBJECTS
Default Null Subject Account for Blank Record

5103 -
510401 -  ..
510402 - Coagulation Control INR 3.1 Above Range Treating Pulmonary Embolism
510403 -
510404 - Follow up ref SDS M4 K66J, ref SDS L5 K66J.
510405 -
510406 - Labs today show INR 3.1 slightly above the prescribed range of 2.0 to
510407 - 3.0. ref SDS 0 PU7Y
510409 -  ..
510410 - During the meeting with the medical team today, slight rise of INR to
510411 - 3.1 could be related to changes in the treatment plan.  On 081219
510412 - treatments with sunitinib and cyclophosphamide were suspended for 1
510413 - week until 081227, and treatment with Methotrexate was ended entirely.
510415 -  ..
510416 - Additionally, Millie recalled taking Coumadin treatment of order by 4
510417 - or 5 hours on 2 consecutive days within the past 3 or 4 days.  This
510418 - change in routine, which has since been corrected, might contribute to
510419 - increasing INR.
510421 -  ..
510422 - On 081126 Millie reported elevated INR 3.4 to Gloria at Kaiser
510423 - Coagulation Control Unit, ref SDS L6 J45H  Millie received a letter
510424 - from Gloria which adjusted the dose of Coumadin required to manage
510425 - Millie's chronic pulmonary embolism condition, now being taken with
510426 - sunitinib and cyclophosphamide taken to treat cancer. ref SDS L7 VQ8V
510427 -
510428 -
510429 -
510430 -
510431 -
510432 -
510433 -
510434 -
510435 -
5105 -